Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Atherosclerosis. 2013 Feb 18;228(1):181–187. doi: 10.1016/j.atherosclerosis.2013.02.004

Table 3.

Associations of EPA with plasma lipids and lipoproteins across APOE genotypes12

E2 (n=333) E3 (n=1459) E4(n=548) p-value interaction
Slope (p-value) Slope (p-value) Slope (p-value)
Lipid profile
HDL-C (mmol/L) 0.074 (0.001) 0.026 (0.08) -0.012 (0.32) 0.0002
Lipoprotein characteristics
Small LDL conc. (nmol/L) 35.06 (0.08) 34.61 (0.03) 84.44 (<0.001) 0.04
Mean LDL size (nm) -0.01 (0.85) -0.02 (0.41) -0.07 (0.006) 0.05
Large HDL conc. (μmol/L) 0.89 (0.001) 0.26 (0.09) -0.01 (0.95) 0.006
Mean HDL size (nm) 0.04 (0.22) 0.00 (0.92) -0.04 (0.09) 0.03
Total HDL conc. (μmol/L) 0.67 (0.03) 0.23 (0.38) -0.28 (0.29) 0.007
1

Values are the slope of DHA on each plasma lipid or lipoprotein in each APOE genotype group (p-values in parentheses). The p-value for interaction is calculated based on test for equality for the three APOE genotype groups..

2

Adjusted for age, sex, race, field center, ancestry informative marker principal components (PC1-PC5), education, smoking status, alcohol use, total intentional exercise, BMI, diabetes. Triglycerides was included as a covariate for outcomes other than triglycerides